Kyowa Kirin Co Ltd - Company Profile
Powered by 
All the data and insights you need on Kyowa Kirin Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Kyowa Kirin Co Ltd Strategy Report
- Understand Kyowa Kirin Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Kyowa Kirin Co Ltd (Kyowa Kirin), a subsidiary of Kirin Holdings Co Ltd, is a biotechnology company focused on research and development. It is involved in the discovery, development, production and commercialization of pharmaceuticals and biotechnology products. The company offers drugs in the areas of nephrology, immunology and allergy, oncology, central nervous system among others. Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, angina pectoris, hypertension, allergic rhinitis, epilepsy, behavioral or personality disorders and others. The company operates through a network of subsidiaries in the US, Europe and Asia. Kyowa Kirin is headquartered in Tokyo, Japan.
Headquarters
Japan
Address
Otemachi Financial City Grand Cube, 1-9-2, Ote-Machi, Chiyoda-Ku, Tokyo, 100-0004
Website
www.kyowakirin.co.jp
Telephone
81 3 52057200
No of Employees
5,974
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4151 (TYO)
Revenue (2022)
$3.3B
11%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
51.5%
(2022 vs 2021)
Market Cap*
$9.5B
Net Profit Margin (2022)
XYZ
36.5%
(2022 vs 2021)
* As of and is in US$
Kyowa Kirin Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pharmaceuticals: | Pasetocin |
| Erythropoietic Stimulating Agent | Adriacin |
| Agent for Hypertension and Angina | Fortimicin |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Plans/Strategy | In February, the company announced its plans to invest US$200 million to establish a pharmaceutical manufacturing facility in Sanford, North Carolina, the US. |
| 2024 | Acquisitions/Mergers/Takeovers | In January, the company acquired Orchard Therapeutics. |
| 2024 | Contracts/Agreements | In January, the company entered into a partnership with LG Chem to market Nephoxil in Korea. |
Competitor Comparison
| Key Parameters | Kyowa Kirin Co Ltd | Takeda Pharmaceutical Co Ltd | Chugai Pharmaceutical Co Ltd | Eisai Co Ltd | Taisho Pharmaceutical Holdings Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Chiyoda-Ku | Chuo-Ku | Chuo-Ku | Bunkyo-Ku | Toshima-Ku |
| State/Province | Tokyo | Tokyo | Tokyo | Tokyo | Tokyo |
| No. of Employees | 5,974 | 49,095 | 7,771 | 11,076 | 8,784 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Masashi Miyamoto, Ph.D. | President; Chief Executive Officer; Director | Executive Board | 2018 | - |
| Takeyoshi Yamashita, Ph.D. | Director; Senior Managing Executive Officer | Executive Board | 2022 | - |
| Motohiko Kawaguchi | Head - Global Finance; Chief Financial Officer | Senior Management | - | - |
| Yasuo Fujii | Chief Strategy Officer | Senior Management | 2023 | - |
| Wataru Murata | Global Human Resources Head; Chief People Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward